Clin2
NCT06337539Possibly a fitNot yet recruiting

Personalized Depression Treatment: Immune Markers and Antidepressant Response

DepressionInflammationAntidepressantsImmunity

Treatments studied

Part of Immune system & allergy, Mental health clinical trials.

This study tests whether certain immune markers and mood symptoms can help predict how well people will respond to antidepressants. Researchers hope to make treatment more personalized for people with depression.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
50 people
Ages
18 years to 65 years
Study type
Observational

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with major depression by a doctor.
  • You are ready to start a new antidepressant treatment.
  • You have not taken any antidepressants, antipsychotics, or mood stabilizers in the past 6 weeks.
  • You do not have active alcohol or drug use problems (past 3 months).
  • You are not pregnant, and you do not have serious medical conditions like autoimmune or immune system disorders.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05644301Recruiting· Phase 3
Blood-marker guided add-on treatment for major depression

This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.

Duffel, Antwerpen
NCT06580041Enrolling by invitation· Phase 4
Precision treatment for major depression

This trial tests a personalized approach to treating major depressive disorder using assessments and brain imaging to match you with the best therapy. It aims to improve outcomes by tailoring care to your specific needs.

San Francisco, California
NCT06136546Recruiting· Phase 2
Infliximab for depression with cognitive problems

This trial tests if a medicine called infliximab, given through an IV, can help improve thinking and memory problems in people with moderate to severe depression who also have high inflammation levels. It aims to see if lowering inflammation can ease both mood and cognitive symptoms.

Boston, Massachusetts
NCT06537921Recruiting
Testing minocycline for depression with obesity

This trial tests whether adding the antibiotic minocycline to your current antidepressant helps people with both depression and obesity. It aims to see if reducing inflammation can improve mood.

London
NCT05466851Recruiting
Study testing anxiety and depression biology and therapy markers

This study looks at “biopsychosocial markers” (biological, psychological, and social signs) in people with major depression and/or anxiety. It aims to understand what changes with treatment and how those changes connect to symptoms like anxiety and depression.

New York, New York
NCT07738497Not yet recruiting
Finding biomarkers to personalize depression treatment

This trial is looking for people with major depression to study how genes and other markers might help doctors choose the best medication. The goal is to make depression treatment more precise and effective.

Hear when a new Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.